GlassScriptPhysician profile
Sarah A Perrin
NPI 1508374141
$1,480.71
in general payments reported to CMS, 2019-2025
29 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.72 · 2022: $274 · 2023: $419 · 2024: $430 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.33 |
| Education | $142.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $231.43 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $173.96 | 2022-2025 | |
| Seagen INC. | $140.14 | 2023 | Tukysa |
| Abbvie INC. | $110.07 | 2024-2025 | |
| Aspira Women'S Health INC | $95.14 | 2023 | Ova1 |
| Servier Pharmaceuticals LLC | $57.24 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $54.37 | 2022-2025 | |
| Daiichi Sankyo INC. | $53.54 | 2023-2024 | Enhertu, Injectafer |
| Azurity Pharmaceuticals, INC. | $53.26 | 2024 | Horizant |
| Axsome Therapeutics, INC. | $43.11 | 2024 | Sunosi |
| Harmony Biosciences LLC | $39.10 | 2025 | |
| Lilly USA, LLC | $38.73 | 2022-2024 | Jaypirca, Retevmo, Verzenio |
| Ipsen Biopharmaceuticals, INC | $38.06 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $37.61 | 2024 | Libtayo |
| Eisai INC. | $35.12 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emmaus Medical, INC. | $29.44 | 2021-2022 | |
| Inspire Medical Systems, INC. | $25.85 | 2025 | Inspire |
| Pharmacyclics LLC, An Abbvie Company | $24.31 | 2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $23.67 | 2023 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $21.58 | 2022 | |
| Incyte Corporation | $21.16 | 2024 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $20.27 | 2022 | |
| Genzyme Corporation | $19.91 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.38 | 2021 | |
| Sobi, INC | $17.38 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.05 | 2022 | |
| Pfizer INC. | $15.21 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $14.96 | 2024 | Lumryz |
| Gilead Sciences, INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Perrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.